IDEAYA starts Phase 1 trial for IDE034, promising B7H3/PTK7 bispecific drug. Targets solid tumors. 30-40% express B7H3/PTK7.
A clinical trial is being conducted to evaluate the safety, tolerance, and pharmacokinetics (PK) of IDE034 in Phase 1 dose escalation. IDE034 is being tested both as a standalone treatment and in conjunction with the company's exclusive PARG inhibitor, IDE161. The target population includes patients with various solid tumor types, with B7H3/PTK7 expression observed in 30-40% of cases. Tumor types under investigation include lung, breast, ovarian, and colorectal cancer.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments